Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)
- 2 June 2016
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 388 (10041), 248-257
- https://doi.org/10.1016/s0140-6736(16)30583-9
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerThe New England Journal of Medicine, 2011
- Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group)Investigational New Drugs, 2011
- Comparison of the pharmacokinetics and pharmacodynamics of S‐1 between Caucasian and East Asian patientsCancer Science, 2010
- A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic CancerBritish Journal of Cancer, 2009
- Randomized Phase III Trial of Adjuvant Chemotherapy with Gemcitabine versus S-1 in Patients with Resected Pancreatic Cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01)Japanese Journal of Clinical Oncology, 2008
- Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral FluoropyrimidineThe New England Journal of Medicine, 2007
- An Early Phase II Study of S-1 in Patients with Metastatic Pancreatic CancerOncology, 2005
- A Randomized Trial of Adjuvant Chemotherapy with Uracil–Tegafur for Adenocarcinoma of the LungThe New England Journal of Medicine, 2004
- A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic CancerThe New England Journal of Medicine, 2004
- Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulatorsAnti-Cancer Drugs, 1996